The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
about
Customized targeted therapy in Hodgkin lymphoma: hype or hope?Therapeutic modulators of STAT signalling for human diseasesPharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaAugmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphomaEndogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancyTargeting oncogenic and epigenetic survival pathways in lymphoma.New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.XIV. The rationale for combining targeted and biological anti-lymphoma drugs.Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.STAT3 inhibitors: finding a home in lymphoma and leukemia.Profile of pacritinib and its potential in the treatment of hematologic disorders.FDG PET/CT imaging as a biomarker in lymphoma.ERK1/2 inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer SGC7901 cells.HiJAKing the epigenome in leukemia and lymphoma.JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages.Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.Signal Inhibition Reveals JAK/STAT3 Pathway as Critical for Bovine Inner Cell Mass Development.Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2.
P2860
Q27002554-56718AE5-8B1B-4AC1-AEB4-C23CBE7E9E95Q33684732-B936B234-06F7-4D1A-AD39-67E85EF197B1Q34301568-D3A031B5-AE98-4ECE-B984-195458AC7EF8Q34648812-2874608E-AB8B-4EAF-AC7F-7B0270CC0881Q35214530-6931444F-0CFE-4E5B-9ADB-B4BC3DFF8C2EQ35740025-6DF38DEC-FCB9-4318-BEFC-3C87FD164D06Q36598782-92AFC7EA-A414-44F7-8216-8FB1E17446EBQ36737884-22F66B53-119F-47C7-ABC7-63DF708C00BDQ38084734-EE21C153-2193-4766-85DD-18C6A14D8222Q38085250-8DF142AC-356F-4582-A798-F9FA0BC9B451Q38115234-F757CF9D-7CCF-4839-85B6-224B70B7BA8CQ38132817-22908AD2-67C8-4C92-B9E6-227F738C9A94Q38164139-97E1F25E-0F9F-4094-9498-D9EC0BD86AD0Q38202556-A9D92CCF-D6E3-4736-92F0-85F95D03E3B2Q38244524-EF65D531-334A-410B-B228-D8F4AAFCFF64Q38312367-2EEA2123-8E9B-4F96-B6FF-43723C014973Q39068091-4A1BA016-8B2F-4438-8128-9C15D55B4D68Q39237403-D474109E-A8DD-4C39-B53C-F4FD04E07C48Q42778549-9A4173F5-0482-4CFD-B04E-B5360BFA9F1DQ42827073-DEEC7CEF-9302-49EA-8A6F-BB9544E62A94Q47140442-1AFA7AE5-35A7-41C0-8A57-D89CAE936117Q48565825-5842FC52-ADFC-4522-BC2A-4E859EA97D11Q49912597-7DF8902F-1A1F-4137-8A87-37A765F78CBEQ51759248-64ED17E1-D572-4BD2-8C4D-EF88E2547A84Q52668197-7A63EB2D-A2DD-4CBE-A2D3-2264F1EB9D0FQ54327831-B9463AAF-6CCC-4680-B8AB-1C795E7ABEC2
P2860
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
@ast
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
@en
type
label
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
@ast
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
@en
prefLabel
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
@ast
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
@en
P2093
P2860
P356
P1433
P1476
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
@en
P2093
H Katayama
P2860
P2888
P356
10.1038/BCJ.2011.46
P577
2011-12-02T00:00:00Z